The vasodilatory beta-blockers
- 22 July 2007
- journal article
- review article
- Published by Springer Nature in Current Hypertension Reports
- Vol. 9 (4) , 269-277
Abstract
Although well established in treating hypertension and cardiovascular (CV) disease, clinical trial data suggest that β-blockers (eg, atenolol) may be less effective than other antihypertensive classes in reducing stroke and CV mortality despite similar blood pressure (BP) reductions. One possible explanation is that atenolol is less effective in reducing central aortic pressure. Newer vasodilating β-blockers may prove more effective in reducing central pressure and cardiovascular events. Carvedilol and labetalol appear to cause vasodilation through α 1-receptor blockade; nebivolol induces endothelium-dependent vasodilation by stimulating nitric oxide bioactivity. Their favorable hemodynamic profile includes reduction of peripheral vascular resistance (PVR) while maintaining or improving cardiac output (CO), stroke volume, and left ventricular function, whereas nonvasodilating β-blockers tend to raise PVR and reduce CO and left ventricular function. Compared with conventional β-blockers, vasodilating β-blockers have beneficial hemodynamic effects including decreased pressure wave reflection from the periphery, leading to decreases in central aortic blood pressure. Larger trials are needed to determine whether reduced central pressure will translate into improved CV outcomes compared with nonvasodilating β-blockers.Keywords
This publication has 70 references indexed in Scilit:
- Nebivolol Inhibits Superoxide Formation by NADPH Oxidase and Endothelial Dysfunction in Angiotensin II–Treated RatsHypertension, 2006
- Basal NO Locally Modulates Human Iliac Artery Function In VivoHypertension, 2005
- Aortic Pressure Augmentation Predicts Adverse Cardiovascular Events in Patients With Established Coronary Artery DiseaseHypertension, 2005
- Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective ??-Blockers in the Treatment of HypertensionHigh Blood Pressure & Cardiovascular Prevention, 2005
- Nebivolol Increases Arterial Distensibility In VivoHypertension, 2004
- The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertensionBritish Journal of Clinical Pharmacology, 1999
- CarvedilolDrugs, 1997
- Carvedilol Inhibits Vascular Smooth Muscle Cell ProliferationJournal of Cardiovascular Pharmacology, 1993
- LabetalolDrugs, 1989
- Labetalol in the Treatment of Hypertension in Elderly and Younger PatientsThe Journal of Clinical Pharmacology, 1987